Adult vs Pediatric Atopic Dermatitis: Epidemiology, Pathogenesis, Comorbidities, and Treatment

Conclusions

• Adult atopic dermatitis is common, affecting roughly 7% of U.S. adults and more adults than children, so it should not be viewed as a rare pediatric-only disease.
• Adult-onset or recurrent atopic dermatitis is real and may account for about one in four adult cases, with onset occurring even in later adulthood and geriatric years.
• Atopic dermatitis should be thought of as heterogeneous across the life course, with different clinical patterns, triggers, and immune signatures in children, younger adults, and older adults.
• Filaggrin mutations help explain early-onset disease but do not account for most adult-onset disease, which appears to have a different and more polygenic genetic architecture.
• Adult-onset disease often shows different immune features than childhood disease, with relatively more Th1/Th17-skewing and less classic Th2 predominance in some adult subsets.
• Clinical morphology changes with age, with adults more likely to show lichenification, papular or psoriasiform lesions, hand eczema, and extensor or truncal patterns, while children more often show acute oozy and flexural disease.
• Adult eczema requires a broader differential diagnosis than pediatric eczema, including allergic and irritant contact dermatitis, stasis dermatitis, drug eruptions, bullous pemphigoid, Grover disease, scabies, and cutaneous T-cell lymphoma.
• Severe atopic dermatitis is associated with important comorbidities including asthma, food allergy, allergic rhinitis, mental health disorders, cardiovascular disease, metabolic disease, osteoporosis/fracture risk, infections, alopecia areata, and urticaria.
• Routine food allergy testing or empiric elimination diets are usually not helpful for atopic dermatitis and can be harmful, especially in children, unless the history strongly suggests a true food-triggered reaction.
• Disease burden is substantial and cumulative, with major effects on sleep, mental health, work, relationships, and long-term life trajectory, so treatment goals should extend beyond skin clearance alone.
• Shared decision-making and patient-reported outcome measures are essential because patients of different ages prioritize different goals, such as sleep, social functioning, side effects, and burden on others.
• Modern topical and systemic therapies are effective across ages, but some data suggest age-related differences in response and that younger patients may sometimes respond better to certain targeted therapies.
• Biologics such as dupilumab appear to work consistently across age groups, while JAK inhibitors provide the fastest and strongest early control but require careful age-related safety consideration.
• Older age increases adverse-event risk for JAK inhibitors and may warrant extra caution, even though efficacy can remain high.
• There is not yet strong evidence that screening for every comorbidity improves outcomes, but clinicians should recognize high-risk associations and intervene pragmatically where appropriate.
• The concept of disease modification is promising, but current evidence is mostly observational, and whether early aggressive treatment truly alters the long-term natural history of atopic dermatitis remains unproven.
• Chronic pruritus of unknown origin and related elderly eczematous eruptions may overlap with atopic dermatitis, but are not yet well standardized and likely include multiple biologically distinct entities.
• Overall, adult atopic dermatitis is not simply larger childhood eczema; it is a distinct, clinically important, and biologically diverse disease that deserves age-tailored diagnosis and management.